- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1059KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 465KB)
Pegcetacoplan – March 2022
Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™
Last updated
15 July 2022